In adults with type 1 diabetes, glucagon glucose AUC did not differ after rapid versus slow decline: 220 ± 49 versus 174 ± 31 mmoL/L x min (P = 0.21).
In plain wordsIn adults with type 1 diabetes, glucagon's glucose response did not significantly differ after rapid versus slow glucose decline.
- Peptide
- Glucagon
- Outcome
- No significant changePositive incremental glucose AUC
- Study
n = 10
- Comparator
- Slow preceding glucose decline
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 150 μg · subcutaneous · 120 minutes observationAs given in this study (human).
Measurements
- Positive incremental glucose AUC
- 220 mmoL/L x min
- rapid-decline visit, mean, SEM 49
- Positive incremental glucose AUC
- 174 mmoL/L x min
- slow-decline visit, mean, SEM 31
- P value
- 0.21
- rapid vs slow decline
Source sentences
The positive incremental area under the glucose curve after administration of low-dose glucagon did not differ between the rapid-decline and slow-decline visits (mean ± SEM: 220 ± 49 vs. 174 ± 31 mmoL/L x min; P = 0.21).
3 context sentences(design, population, supporting numbers)
Ten adults with insulin pump-treated type 1 diabetes were included in this randomized, single-blind, two-way crossover study.
Using a hyperinsulinaemic clamp technique, plasma glucose levels were reduced with either a rapid or slow decline rate while maintaining fixed insulin levels.
When the plasma glucose level reached 3.9 mmoL/L, insulin and glucose infusions were discontinued and 150 μg subcutaneous glucagon was administered, followed by 120 minutes of plasma glucose monitoring.